

In-Depth Analysis Of The Global Acquired Immunodeficiency Syndrome (AIDS) Market: Key Drivers, Trends, Growth

*Updated 2025 Market Reports Released:
Trends, Forecasts to 2034 – Early
Purchase Your Competitive Edge Today!*

LONDON, GREATER LONDON, UNITED KINGDOM, March 24, 2025

/EINPresswire.com/ -- Over the past few years, the [acquired](#)

[immunodeficiency syndrome aids](#)

[market](#) has witnessed significant growth. The market size rose from \$32.09 billion in 2024 and is projected to reach \$33.85 billion in 2025, with a compound annual growth rate CAGR of 5.5%.

The rise in the market witnessed during the historical period was driven predominantly by increasing HIV infection rates, an uptick in government funding for HIV treatment, the broadening of global awareness programs, improving diagnostic capabilities, and growing support from non-governmental organizations.

Considering this remarkable growth trajectory, what can we expect for the AIDS market size in the near future?

The next few years are set to witness a substantial surge in the size of the AIDS market. The market is forecasted to reach \$41.57 billion in 2029 at a compound annual growth rate CAGR of 5.3%. This increase during the forecast period can be attributed to the rising demand for long-acting injectable therapies, the surge in the adoption of pre-exposure prophylaxis PrEP, a boost in HIV cure research investment, the broadening of telemedicine services for HIV care, an increasing focus on personalized medicine, and the heightened consciousness about early HIV diagnosis. Major trends in the forecast period include the transition towards single-tablet regimens, a growing preference for injectable and implantable HIV treatments, the swelling demand for digital health solutions in HIV management, a rise in interest in HIV cure strategies, and the expanding role of artificial intelligence in drug discovery.

Get Your Free Sample Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=21076&type=smp>

So, what factors are expected to be the primary drivers of growth in the Acquired



Immunodeficiency Syndrome AIDS market?

The increasing rates of HIV infections are a major propulsion factor for the growth of the global AIDS market. HIV infections, caused by the Human Immunodeficiency Virus HIV, attack the immune system, ultimately reducing the body's ability to fend off infections and diseases. The rise in HIV infections can be attributed to factors such as involvement in unprotected sexual intercourse with an infected person, sharing needles or syringes, receiving contaminated blood products, having multiple sexual partners, and weakened immunity or pre-existing sexually transmitted infections. Early diagnosis, access to effective antiretroviral therapies, prevention strategies, and robust healthcare systems are crucial elements of AIDS management. This increased scope of management plays a part in better control of the virus's spread, which, in turn, drives the AIDS market.

Order Your Report Now For A Swift Delivery:

<https://www.thebusinessresearchcompany.com/report/acquired-immunodeficiency-syndrome-aids-global-market-report>

Who Are The Leading Companies In The Market?

Companies leading the charge in the AIDS market include Pfizer Inc., Johnson and Johnson, F. Hoffmann-La Roche Ltd, Merck & Co. Inc., Sanofi SA, Bristol-Myers Squibb Company, Abbott, GSK plc, Takeda Pharmaceuticals, Gilead Sciences, Viatrix Inc., Teva Pharmaceuticals, Aurobindo Pharma, Cipla Ltd, Shionogi and Co., Dr. Reddy's Laboratories, Lupin, Hetero Drugs Limited, Glenmark Pharmaceuticals Limited, ViiV Healthcare.

A significant trend observed among leading companies is their increasing focus on the development of innovative therapies such as long-acting injectables. These not only improve patient compliance but also reduce the frequency of dosing, providing a more convenient alternative to daily oral antiretroviral treatments.

What Are The [Segments In The AIDS Market?](#)

The AIDS market is distinguished by several segments including Type Human Immunodeficiency Virus 1, 2, Drug Type Nucleoside-Analog Reverse Transcriptase Inhibitors, Non-Nucleoside Reverse Transcriptase Inhibitors, Fusion Inhibitors, CCR5 Antagonists And Post-Attachment Inhibitors, Protease Inhibitors, Integrase Inhibitors, Pre-Exposure Prophylaxis And Post-Exposure Prophylaxis, Route Of Administration Oral, Parenteral, Application Hospital Pharmacy, Retail Pharmacy, Other Applications, Distribution Channel Offline, Online.

Regionally, North America led the AIDS market in 2024. In contrast, Asia-Pacific is projected to be the fastest-growing region in the forecast period. The global AIDS market spans several geographic regions, including Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Browse Through More Similar Reports By [The Business Research Company](#):

Antidepressants Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/antidepressant-global-market-report>

Branded Generics Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/branded-generics-global-market-report>

Psychiatrists Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/psychiatrists-global-market-report>

About The Business Research Company:

With over 15000+ reports covering 27 industries over 60+ geography, The Business Research Company offers comprehensive, data-rich research and insights. With a database of 1,500,000 secondary research, unique insights from industry leaders, you can get the information you need to stay ahead of the competition.

Get in touch:

The Business Research Company: <https://www.thebusinessresearchcompany.com/>

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us: info@tbrc.info

Stay connected:

LinkedIn: <https://in.linkedin.com/company/the-business-research-company>

YouTube: https://www.youtube.com/channel/UC24_f10rV8cR5DxICpgmyFQ

Global Market Model: <https://www.thebusinessresearchcompany.com/global-market-model>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

This press release can be viewed online at: <https://www.einpresswire.com/article/796543940>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.